New discovery for our fellow cancer Malaysians?

Panda asks:

Question

We have discovered a natural supplements which may help cancer patients in the long run. Cancer cell clings on our cell for nutrients (food). Once they have enough nutrients, they then to spread through their capillaries to the other parts of the body. The duty of this supplement is to act as a barrier, by stopping the supply of nutrients from our cell to the tumour. This on the other hand, starved the tumour and eventually shrink it. The supplements have been tested on several cancer patients and proved to be effective. Since the product is natural based, it has no side effects. The supplement is effective for most of the cancers except for leukimia and lymph cancer. Pregnant ladies, children under 12 years of age and patients who has undergone operation in less than a month are not allowed to consume the supplement. For best results on cancer patients, depending on severeness, they are required to consume at least three bottles of the supplements, which is three months supply.

Answer

Sounds like a sales pitch to me. Any type of supplement that 'works' in this manner should have documented scientific evidence to back up the claim. Can you provide the link to documented evidence from the Clinical Trials done for this supplement.

Clinical Research Centre: Ministry of Health Malaysia
http://www.crc.gov.my/default.asp?page=/clinicalTrial/index

Related Products

The Complete T. Rex/How Stunning New Discoveries Are Changing Our Understanding of the World's Most ... Book [Used]

(more details)
A look at the Tyrannosaurus Rex discusses the animal's speed, its warm-bloodedness, its dimensions and anatomy, and its gender differences, offering excavation photos and line drawings. (Glyde, miscellaneous)

Bioinformatics in Cancer and Cancer Therapy (Cancer Drug Discovery and Development)

(more details)
Bioinformatics can be loosely defined as the collection, classification, storage, and analysis of biochemical and biological information using computers and mathematical algorithms. Although no single person or group started the field wholly on their own, Temple Smith, Ph.D., a professor at Boston University, is generally credited with coining the term. Bioinformatics represents a marriage of biology, medicine, computer science, physics, and mathematics, fields of study that have historically ex (Amazon.com, none)

Cell Cycle Inhibitors in Cancer Therapy (Cancer Drug Discovery and Development)

(more details)
Temple Univ., Philadelphia, PA. Text provides recent critical research findings for clinical practice and presents their impact on diagnostics, prognostics, and therapeutics of cancer, AIDS, and cardiovascular disease. Written in expanded-outline format. (Amazon.com, none)

The No-Dairy Breast Cancer Prevention Program: How One Scientist's Discovery Helped Her Defeat Her Cancer

(more details)
One out of nine women in the United States will develop breast cancer in her lifetime. For too long, women have erroneously believed that there is little or nothing they can do to prevent this dread illness. Our major medical efforts are directed toward detecting and treating, rather than preventing, breast cancer. Professor Jane Plant, one of Britain's most eminent scientists, contracted breast cancer in 1987. When orthodox medicine gave up and she was told she had only three months to live (Amazon.com, none)

Cancer Therapeutics: Experimental and Clinical Agents (Cancer Drug Discovery and Development)

(more details)
Dana-Farber Cancer Institute, Boston, MA. Reviews existing and potential anticancer drugs and therapies. Companion to Anticancer Drug Development Guide by Teicher. For researchers and practitioners. 29 contributors, 19 U.S. DNLM: Antineoplastic agents. (Amazon.com, none)

Antifolate Drugs in Cancer Therapy (Cancer Drug Discovery and Development)

(more details)
This collection of cutting-edge reviews comprehensively examines the current status of novel antifolates, an important class of anticancer drugs. The distinguished contributors discuss the preclinical and clinical pharmacology of methotrexate, other dihydrofolate reductase inhibitors, 5-fluorouracil, and the new generation of antifolates-the thymidylate synthase and glycinamide ribonucleotide formyltransferase inhibitors. In addition, they review in depth the modulation of antifolate drugs, fola (Amazon.com, none)

Platinum-Based Drugs in Cancer Therapy (Cancer Drug Discovery and Development)

(more details)
Leading international experts comprehensively review all aspects of platinum anticancer drugs and their current use in treatment, as well as examining their future therapeutic prospects. Writing from a variety of disciplines, these authorities discuss the chemistry of cisplatin in aqueous solution, the molecular interaction of platinum drugs with DNA, and such exciting new areas as DNA mismatch repair and replicative bypass, apoptosis, and the transport of platinum drugs into tumor cells. The em (Amazon.com, none)

Farnesyltransferase Inhibitors in Cancer Therapy (Cancer Drug Discovery and Development)

(more details)
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Standard reference for the pathbreaking use of FTIs and GGTIs in anticancer therapy. Offers basic and clinical researchers a comprehensive treatment of the scientific and medical aspects of farnesyltransferase inhibitors. DNLM: Dimethyulalytranstransferase--antagonists. (Amazon.com, none)

Matrix Metalloproteinase Inhibitors in Cancer Therapy (Cancer Drug Discovery and Development)

(more details)
Cutting-edge investigators review the current status of the entire field, from the biology of MMPs through the current clinical studies. The authors include many leading scientists from pharmaceutical companies who present all the latest concepts and results on the preferred design strategies for MMP inhibitors, their molecular mechanisms, and their substrates. In addition, they fully describe their personal research on specific MMP inhibitors, detailing vanguard design strategies, their in vitr (Amazon.com, none)

Hormone Therapy in Breast and Prostate Cancer (Cancer Drug Discovery and Development)

(more details)
Northwestern Univ., Chicago, IL. Presents a review of the endocrine treatment of breast and prostate cancer by the originators, a model for making new discoveries in the chemoprevention of cancer, a synthesis of history and clinical practice, and a guide for progress. DNLM: Breast Neoplasms--drug therapy. (Amazon.com, none)

Apoptosis and Cancer Chemotherapy (Cancer Drug Discovery and Development)

(more details)
Univ. of Manchester, UK. Focuses on the key issues in apoptosis as they affect cancer pathology and chemotherapy. Presents potential targets for tumor therapy and control points for cancer, viral infection, neurodegenerative disorders, and stroke. For researchers and practitioners. DNLM: Neoplasms--drug therapy. (Amazon.com, none)

Tumor Suppressor Genes in Human Cancer (Cancer Drug Discovery and Development)

(more details)
Harvard Medical School, Boston, MA. Analyzes the major tumor suppressors and the pathways into which they fit, describes the broad roles of tumor suppressor pathways in cell regulation, discusses animal models, and attempts to link molecular progress in cancer research with improved cancer therapy. DNLM: Genes, Suppressor, Tumor. (Amazon.com, none)

Drug Delivery Systems in Cancer Therapy (Cancer Drug Discovery and Development)

(more details)
Comprehensively reviews the drug delivery systems for cancer chemotherapy. Discusses the convention as well as the unconventional methods of drug administration and provides an overview of opportunities for future drug development. Focuses primarily on small molecule delivery. DNLM: Drug Delivery Systems--methods. (Amazon.com, none)

Tumor Targeting in Cancer Therapy (Cancer Drug Discovery and Development)

(more details)
Univ. of Laval, Quebec, Canada. Presents a critical review of the state-of-the art of tumor targeting from laboratory to bedside. Gives a review of the principles and techniques of targeting, numerous examples of applications with drugs, and more. Outline format. DNLM: Neoplasms--immunology. (Amazon.com, none)

Targets for Cancer Chemotherapy (Cancer Drug Discovery and Development)

(more details)
Univ. of Glasgow, Scotland. Shows how our understanding of critical molecular targets in cancer cells can be applied to cancer drug discovery to provide new drug discovery platforms for future development and for new target-based medicine for cancer patients. Expanded-outline format. DNLM: Neoplasms--drug therapy. (Amazon.com, none)

Camptothecins in Cancer Therapy (Cancer Drug Discovery and Development)

(more details)
A critical review our current understanding of camptothecins, their shortcomings, and of the possibilities for improving their clinical performance. The authors discuss new camptothecin analog development, drug delivery issues for optimizing their anticancer activity, and their potential use in a variety of different cancers. Additional chapters describe what is known about the biochemistry, the pharmacology, and the chemistry of the camptothecins, including the mechanism of topoisomerase and ho (Amazon.com, none)

Chemoradiation in Cancer Therapy (Cancer Drug Discovery and Development)

(more details)
Vanderbilt Univ., Nashville, TN. Offers an understanding of current and future strategies available for the treatment of solid tumors by chemotherapeutic agents. Includes the integration of new molecular-targeted agents and discussions at the molecular level. Electronic format not yet available. DNLM: Neoplasms--drug therapy. (Amazon.com, none)

Combination Cancer Therapy: Modulators and Potentiators (Cancer Drug Discovery and Development)

(more details)
Expert physician-scientists and clinicians review those combinations of novel target agents classic chemotherapies that hold the most promise for the future of medical oncology, and detail their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cycle (the CDKs), signal transduction events (PKC and NF-kB), apoptosis (bcl-2), as well as focu (Amazon.com, none)

Nucleic Acid Therapeutics in Cancer (Cancer Drug Discovery and Development)

(more details)
A cutting-edge review of the important issues underlying the therapeutic use of nucleic acid-mediated gene silencing. Topics range from basic methodology and delivery to targeting and clinical targets. The authors thoroughly explain the latest developments in RNA biology, as well as the underpinnings of RNA interference, oligodeoxynucleotide delivery into cells, and strategies for targeting these molecules to accessible regions within the mRNA. They also provide some examples of how these new th (Amazon.com, none)

DNA Repair in Cancer Therapy (Cancer Drug Discovery and Development)

(more details)
A comprehensive review of the recent developments in DNA repair that have potential for translational and clinical applications. The authors explain in detail the various mechanisms by which cancer cells can circumvent anticancer therapy and limits its usefulness in patients. They also review the clinical impact of such novel inhibitors of DNA repair mechanisms as methylguanine-DNA-methyltransferase. Also examined are inhibitors of other DNA repair enzymes such as PARP and DNA-PK, now under deve (Amazon.com, none)

Antiangiogenic Agents in Cancer Therapy (Cancer Drug Discovery and Development)

(more details)
Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials. Optimizing the therapeutic potential of antiangiogenic agents in combination with the other therapies in the armamentarium to fight cancer will be an on-going challenge. Antiangiogenic Agents in Cancer Therapy, Second Edition provides a current, up-dated perspective on the state of the art (Amazon.com, none)

Checkpoint Responses in Cancer Therapy (Cancer Drug Discovery and Development)

(more details)
Extensive research has uncovered a set of molecular surveillance mechanisms commonly called checkpoints which tightly monitor cell-cycle processes. Today s anticancer drug development has identified many of these cell-cycle checkpoint molecules as effective targets. Research now promises to uncover a new generation of anticancer drugs with improved therapeutic indices based on their ability to target emerging checkpoint components. Checkpoint Responses in Cancer Therapy summarizes the advances m (Amazon.com, none)

Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy: Molecular Mechanisms and Clinical Applications (Cancer Drug Discovery and Development)

(more details)
Following the serendipitous discovery of cisplatin by Barnett Rosenberg back in 1965 and its approval in 1978 by the Food and Drug Administration, a growing number of platinum compounds have emerged as fundamental components for the treatment of different types of cancer. Although replaced by the better tolerated analogue carboplatin, cisplatin itself is still an important tool for the treatment of germ cell tumors and cancers of head and neck. The introduction into the clinic of the DACH platin (Amazon.com, none)

Cancer Therapeutics: Experimental and Clinical Agents (Cancer Drug Discovery and Development)

(more details)
Dana-Farber Cancer Institute, Boston, MA. Reviews existing and potential anticancer drugs and therapies. Companion to Anticancer Drug Development Guide by Teicher. For researchers and practitioners. 29 contributors, 19 U.S. DNLM: Antineoplastic agents. (Amazon.com, none)

Cancer Biomarkers: Analytical Techniques for Discovery (Wiley - Interscience Series on Mass Spectrometry)

(more details)
Tools, techniques, and progress in cancer biomarkers discovery The completion of a number of gene sequencing projects, recent advances in genomic and proteomic technologies, and the availability of powerful bioinformatics tools have led to promising new avenues and approaches in the search for cancer biomarkers. This book provides a comprehensive overview of current methodologies and technologies. It discusses biomarker discovery as a whole, rather than focusing on one specific marker or (Amazon.com, none)

Related Articles

Related Questions


Search products, articles, reviews and more - explore details below

© ShopAllThings All rights reserved.